Investigation Report on China Letrozole Market, 2010-2019
|出版商||China Research and Intelligence||商品編碼||337516|
|出版日期||內容資訊||英文 20 Pages
|Letrozole的中國市場:2010年∼2019年 Investigation Report on China Letrozole Market, 2010-2019|
|出版日期: 2015年08月18日||內容資訊: 英文 20 Pages||
Currently, breast cancer has become the first killer of women with new cases reaching about 1.2 million and 0.5 million women dying of it each year.
According to Breast Cancer in China which was published in 2014, the number of new cases and deaths in China respectively accounted for 12.2% and 9.6% of the world sum. And the growth rate of China doubled that of the world. According to the statistics, breast cancer with increasing incidence is the most common malignant cancer for Chinese women. And the average age at onset is 10-15 years younger than that in Europe and America. As the third generation of aromatase inhibitor developed by Novartis, letrozole entered United Kingdom first in 1996 and the US in 1997 before being widely used as the first-line drug for advanced breast cancer and as the second-line drug for breast cancer. At home, Jiangsu Hengrui Medicine Co., Ltd was approved to market letrozole under the trade name of Furui in 1999, followed by Femara of Novaris in 2003.
According to CRI's market survey, letrozole develops fast after entering China with sales value rising from about CNY 20 million in 2005 to over CNY 300 million in 2014 and CAGR during this period reaching 35.1%. As Femara of Novartis is priced two times higher than local products, its sales volume only accounted for less than 50% of the sum despite its market share of 73.62% in 2014. The gradual decrease in Novatis's market share, however, constitutes a great opportunity for local enterprises. Currently, there are only two kinds of letrozole available in the Chinese market, indicating a high entry barrier and a large market.
Studies have shown the uniqueness of breast cancer in China: special fertility pattern due to family planning as well as modern lifestyle like high-fat diet and little exercise increases the risk of breast cancer.
It is expected that letrozole will enjoy a vast demand in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: